Medication affordability and access; general diabetes prevention, 340B, monitoring FDA reform, changes and new programs. SAFE Drugs Act (HR6509/S3794). FDA actions on drug compounding and illicit drugs. Issues related to TrumpRX.
2026 · 3rd Quarter (July 1 - Sep 30)
NOVO NORDISK INC.
Filed by WILLIAMS AND JENSEN, PLLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- WILLIAMS AND JENSEN, PLLC
- Client
- NOVO NORDISK INC.
- Filing UUID
- e787253d-ea9e-4d2b-852e-2843f183063d
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Support for obesity drug coverage and access.
Treat and Reduce Obesity Act; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. Issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Issues related to corporate tax and international tax including related domestic and international tax issues for reconciliation legislation; monitor implementation of PL 119-21.
General issues related to patent protections.
Issues related to China WRT the BINSA bill. Monitoring 232 investigations.
Issues related to China WRT the BINSA bill.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.